In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Opus Genetics Inc (NASDAQ: IRD) closed at $0.83 down -8.95% from its previous closing price of $0.91. In other words, the price has decreased by -$8.95 from its previous closing price. On the day, 0.53 million shares were traded. IRD stock price reached its highest trading level at $0.958 during the session, while it also had its lowest trading level at $0.81.
Ratios:
For a deeper understanding of Opus Genetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.63 and its Current Ratio is at 6.63. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 21 ’24 when YERXA BENJAMIN R bought 10,000 shares for $0.98 per share. The transaction valued at 9,834 led to the insider holds 342,800 shares of the business.
Magrath George bought 90,294 shares of IRD for $91,215 on Nov 15 ’24. The Chief Executive Officer now owns 483,244 shares after completing the transaction at $1.01 per share. On Nov 18 ’24, another insider, Magrath George, who serves as the Chief Executive Officer of the company, bought 9,706 shares for $1.02 each. As a result, the insider paid 9,943 and bolstered with 492,950 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRD now has a Market Capitalization of 26201854 and an Enterprise Value of -10433181. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 0.63. Its current Enterprise Value per Revenue stands at -1.245 whereas that against EBITDA is 0.354.
Stock Price History:
Over the past 52 weeks, IRD has reached a high of $3.40, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -27.31%, while the 200-Day Moving Average is calculated to be -45.94%.
Shares Statistics:
For the past three months, IRD has traded an average of 168.00K shares per day and 226940 over the past ten days. A total of 26.20M shares are outstanding, with a floating share count of 25.99M. Insiders hold about 17.68% of the company’s shares, while institutions hold 8.02% stake in the company. Shares short for IRD as of 1732838400 were 879038 with a Short Ratio of 5.23, compared to 1730332800 on 937096. Therefore, it implies a Short% of Shares Outstanding of 879038 and a Short% of Float of 2.91.
Earnings Estimates
The stock of Opus Genetics Inc (IRD) is currently being evaluated by 3.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.29 and low estimates of -$0.29.
Analysts are recommending an EPS of between $0.02 and -$1.15 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.82, with 3.0 analysts recommending between -$0.32 and -$1.03.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $11.1M this quarter.It ranges from a high estimate of $26.54M to a low estimate of $2.88M. As of the current estimate, Opus Genetics Inc’s year-ago sales were $1.69MFor the next quarter, 3 analysts are estimating revenue of $2M. There is a high estimate of $2M for the next quarter, whereas the lowest estimate is $2M.
A total of 3 analysts have provided revenue estimates for IRD’s current fiscal year. The highest revenue estimate was $33.23M, while the lowest revenue estimate was $9.57M, resulting in an average revenue estimate of $17.8M. In the same quarter a year ago, actual revenue was $19.05MBased on 4 analysts’ estimates, the company’s revenue will be $19.57M in the next fiscal year. The high estimate is $39.46M and the low estimate is $12.2M.